Pfizer Deal With Teva Allows For Entry Of Generic Ellence Ahead Of Patent Expiry
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva will pay $70 mil. to Pfizer to resolve patent litigation over generic versions of Zithromax and Idamycin.